Facts & Figures

  • 1.9 million
    New Incidents of Colon Cancer*

    *Source: GLOBOCAN 2020

  • 50 million
    Colonoscopies Performed

    *Numbers for the US, Canada, Germany, France, Italy, Spain, the UK, Japan, China, South Korea, Australia and India.
    As of 2019

  • 100
    Diseases or Conditions Treated

    At Olympus we have versatile medical devices
    with the ability to treat approximately
    100* diseases or conditions

    *As of March 2022

  • TOP 4
    Cancers Treated

    Olympus provides products/solutions for lung, stomach, colon and prostate cancers - the top 4* highest incidence of cancers
    *Top 4 highest incidence of caners excluding breast cancer, as of March 2022.
    Source: GLOBOCAN 2020

  • 31,557
    Employees Worldwide*

    Countries or Regions*

    *As of March 2022

  • ¥737.1bn
    Total Medical
    Revenue FY2022*

    Medical Business occupies
    the largest part of our revenue

    *Figures are fiscal year revenues as of March 2022

  • 70%
    Global Market Share*

    Olympus is the leader in
    gastrointestinal endoscopic equipment

    *As of Nov 2021

  • 70%
    Olympus R&D*

    are dedicated to the medical business.

    *Research and development for fiscal year ending March 2022.

  • 291

    Since 1966, Olympus has been consistently
    honored with national and international design
    awards for its innovative product designs.*

    *As of March 2022

  • 17,000

    across our product portfolio*

    *As of March 2022

  • CO2“0”
    Net zero CO2 emissions by 2030

    We set as a target of achieving net zero CO2 emissions by 2030 from our site operations

  • TOP 100
    Global Innovator

    Since 2012 to 2020, and in 2022, Olympus has been
    awarded as one of the top 100 most
    innovative companies in the world.
    https://clarivate.com/top-100-innovators/ 新規タブで開きます